ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System
September 19 2023 - 8:31AM
ReShape Lifesciences® (Nasdaq:
RSLS), the premier physician-led weight loss and metabolic
health solutions company, today announced that the company has
significantly strengthened the patent portfolio related to its
Obalon® Balloon System. Specifically, the U.S. Patent and Trademark
Office (USPTO) has granted one patent and provided the company with
a Notice of Allowance for two additional patents, providing
foundational protection of the system.
- Granted U.S. Patent No.
11,737,899, entitled “Intragastric Device,” covers claims
for an intragastric balloon system with a needle assembly
comprising a catheter needle sleeve and needle for inflation of the
balloon system, among other claims.
- Notice of Allowance for
patent application 16/993,110, entitled, “Pressure Control
System For Intragastric Device.” If issued, the patent would
include claims directed to systems and methods for inflating an
intragastric device. The allowed application is a continuation of
issued U.S. Patent No. 10,772,752 issued September 15, 2020. This
patent family has an estimated patent term to at least October
2037.
- Notice of Allowance for
patent application 17/581,792, entitled, “Intragastric
Device.” When issued, the patent will cover claims for an
intragastric balloon system, comprising a capsule configured to be
swallowable by a patient and to degrade in a gastric environment,
with a balloon compacted and contained within the capsule, the
balloon including an outer and inner surface, an interior cavity, a
fill valve and release valve wherein the fill valve and release
valves are separate valves, among other claims.
“Granting of the one patent and receipt of two
additional patent allowances for the Obalon Intragastric Balloon
System, which, together provide foundational protection, is a
critical achievement and further enhances the strength of the
intellectual property around our product portfolio,” stated Paul F.
Hickey, President and Chief Executive Officer of ReShape
Lifesciences. “Since filing our first application for this product
in 2011, we have accumulated over 50 patents around the
intragastric balloon system. Additionally, ReShape has amassed a
family of more than 160 patents and a number of patents pending for
a variety of novel, and protected inventions. Moving forward, we
will continue to reinforce our intellectual property rights around
both our product portfolio and commercialization efforts, while
also taking offensive action to defend our position, when
necessary, utilizing non-dilutive funding.”
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and
metabolic health-solutions company, offering an integrated
portfolio of proven products and services that manage and treat
obesity and metabolic disease. The FDA-approved Lap-Band® System
provides minimally invasive, long-term treatment of obesity and is
an alternative to more invasive surgical stapling procedures such
as the gastric bypass or sleeve gastrectomy. ReShapeCare™ is a
virtual weight-management program that supports lifestyle changes
for all weight loss patients led by board-certified health coaches
to help them keep the weight off over time. The recently launched
ReShape Marketplace™ is an online collection of quality wellness
products curated for all consumers to help them achieve their
health goals. The investigational Diabetes Bloc-Stim
Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve
block and stimulation technology platform for the treatment of type
2 diabetes and metabolic disorders. The Obalon® balloon technology
is a non-surgical, swallowable, gas-filled intra-gastric balloon
that is designed to provide long-lasting weight loss. For more
information, please visit www.reshapelifesciences.com.
Forward-Looking Safe Harbor
Statement This press release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Actual results could differ materially from
those discussed due to known and unknown risks, uncertainties, and
other factors. These forward-looking statements generally can be
identified by the use of words such as "expect," "plan,"
"anticipate," "could," "may," "intend," "will," "continue,"
"future," other words of similar meaning and the use of future
dates. Forward-looking statements in this press release include
statements about our future intellectual property protection
measures. These and additional risks and uncertainties are
described more fully in the company's filings with the Securities
and Exchange Commission, including those factors identified as
"risk factors" in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q. We are providing this
information as of the date of this press release and do not
undertake any obligation to update any forward-looking statements
contained in this document as a result of new information, future
events or otherwise, except as required by law.
CONTACTSReShape Lifesciences Investor
Contact:Thomas StankovichChief Financial
Officer949-276-6042ir@ReShapeLifesci.com
Investor Relations Contact:Rx
Communications GroupMichael
Miller(917)-633-6086mmiller@rxir.com
ReShape Lifesciences (NASDAQ:RSLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
ReShape Lifesciences (NASDAQ:RSLS)
Historical Stock Chart
From Apr 2023 to Apr 2024